Jiangsu Kangbeide Pharmaceutical Co., Ltd.

The rivastigmine transdermal patch (trade name: Exelon, 9.5 mg (10 cm2)) licensed by Novartis Europharm Limited was used as the reference preparation, and the rivastigmine transdermal patch developed by Jiangsu Kangbi Pharmaceutical Co., Ltd. was used as the test preparation. The human bioequivalence of the two preparations was evaluated through a single-center, randomized, open, single-dose, two-period, double-crossover clinical study. At the same time, the safety of the test preparation and the reference preparation in healthy Chinese subjects was observed.

The main purpose of the study is to use the maleic acid afatinib tablets licensed by Boehringer Ingelheim International GmbH as the reference preparation and the maleic acid afatinib tablets developed by Jiangsu Kangbi Pharmaceutical Co., Ltd. as the test preparation to evaluate the bioequivalence of the two preparations in the fasting state through a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

The main purpose of the study is to use the tofacitinib citrate tablets certified by PF PRISM C.V. as the reference preparation and the tofacitinib citrate tablets developed by Jiangsu Kangbi Pharmaceutical Co., Ltd. as the test preparation, and to evaluate the bioequivalence of the two preparations in the fasting and postprandial state through a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.